Price versus value
- Price
- $376.90
- Fair value
- $448.25
- Potential value
- $578.10
- As of
- 2026-09-18
Main upside reason
Accelerating clinical margin recovery in OptumHealth combined with commercial health benefit premium repricing that absorbs medical cost inflation, driving operating margins from 4.24% in FY2025 toward historical levels of 6.50% and expanding fair value toward Potential value of USD 578.10.
Main risk
CMS enacts unfavorable statutory Medicare Advantage rate adjustments or expands risk-adjustment audits.
We rate UnitedHealth Group a Buy. The company's massive scale in health benefits and integrated pharmacy services positions it for steady cash generation and earnings recovery, offering attractive upside from the report-date price to our Fair value.
Our rating is Buy. For an investor, this means UnitedHealth Group offers an attractive balance of steady compounding and share price appreciation, supported by leading positions in health benefits and healthcare services.
The report was prepared at a price of USD 376.90 on September 18, 2026. This price trades at a 15.92% discount to our Fair value of USD 448.25. If clinical care margins recover faster than expected, the shares could reach Potential value of USD 578.10.4
The main risk that would change our view is regulatory rate pressure from Medicare and Medicaid, which account for 44.0% of consolidated . If federal payment benchmarks are cut or risk-adjustment coding audits tighten, premium yields per member would decline while medical utilization remains elevated. A reader would see this happen through consolidated dropping below 3.50% and annual falling below $12,000M.